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ABSTRACT
Background Alternatives to prospective informed 
consent enable the conduct of paediatric emergency and 
critical care trials. Research without prior consent (RWPC) 
involves practitioners approaching parents after an 
intervention has been given and seeking consent for their 
child to continue in the trial. As part of an embedded 
study in the ’Emergency treatment with Levetiracetam 
or Phenytoin in Status Epilepticus in children’ (EcLiPSE) 
trial, we explored how practitioners described the trial 
and RWPC during recruitment discussions, and how well 
this information was understood by parents. We aimed 
to develop a framework to assist trial conversations in 
future paediatric emergency and critical care trials using 
RWPC.
Methods Qualitative methods embedded within 
the EcLiPSE trial processes, including audiorecorded 
practitioner–parent trial discussions and telephone 
interviews with parents. We analysed data using 
thematic analysis, drawing on the Realpe et al (2016) 
model for recruitment to trials.
Results We analysed 76 recorded trial discussions 
and conducted 30 parent telephone interviews. For 19 
parents, we had recorded trial discussion and interview 
data, which were matched for analysis. Parental 
understanding of the EcLiPSE trial was enhanced when 
practitioners: provided a comprehensive description of 
trial aims; explained the reasons for RWPC; discussed 
uncertainty about which intervention was best; provided 
a balanced description of trial intervention; provided a 
clear explanation about randomisation and provided 
an opportunity for questions. We present a seven- 
step framework to assist recruitment practice in trials 
involving RWPC.
Conclusion This study provides a framework to 
enhance recruitment practice and parental understanding 
in paediatric emergency and critical care trials involving 
RWPC. Further testing of this framework is required.
INTRODUCTION
Conducting clinical trials in paediatric emergency 
and critical care settings is challenging for several 
reasons, primarily over consent. Previously, a key 
obstacle was the need to administer interventions 
immediately in life- threatening situations, with no 
time to seek prospective informed consent from 
parents for their child’s participation. However, 
clinical trials legislation1 2 enables children to be 
entered into a trial without prior consent, termed 
‘Research Without Prior Consent (RWPC)’. 
This involves a member of the research team 
approaching parents after the life- threatening situa-
tion has passed. At this point, they are informed of 
their child’s enrolment into the trial, and consent 
is sought for continued participation.3 Studies have 
shown parents support RWPC provided they are 
Key messages
What is already known on this subject
 ► Conducting pragmatic randomised controlled 
trial in paediatric emergency and critical care 
settings can be challenging, particularly in life- 
threatening conditions which preclude seeking 
prospective informed consent for research 
participation.
 ► Clinical trials legislation enables children to 
be entered into a trial without prior informed 
consent .
 ► Practitioners may be anxious about 
approaching families and explaining their 
child’s research participation without prior 
consent, although studies have shown how 
families are supportive of research without 
prior consent to enable important research.
What this study adds
 ► Recruitment discussions in paediatric 
emergency and critical care settings are distinct 
from trials that have time for informed consent 
discussions.
 ► This study provides insight into discussions 
between parents and researchers in a UK 
emergency medicine- led trial and identifies 
recruitment practices that facilitate parental 
understanding of trial purposes and research 
without prior consent.
 ► We present a seven- step framework to assist 
practitioners in discussing future trials with 
parents who may not be aware that their child 
has been entered into a clinical trial without 
their prior informed consent.
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approached at the appropriate time and the reasons are clearly 
described as reflected in high consent rates in such trials.4 5 
Healthcare professionals also support RWPC, even though those 
unfamiliar with RWPC may be anxious about approaching and 
discussing this with parents.6 7 Guidance on RWPC8 has been 
incorporated into the protocols of the first UK trials to use this 
process. However, the quality and content of these trial recruit-
ment discussions, as well as parental understanding of practi-
tioner explanations of RWPC, has not yet been explored.
Qualitative research helps understand and optimise recruit-
ment processes in randomised controlled trial (RCTs), including 
communication between the patient and the enrolling profes-
sional.9 10 Realpe et al11 analysed recordings of informed consent 
consultations in a surgical feasibility study (UK FASHIoN- trial) 
to develop and test a framework for good recruitment practice. 
Their six- step model included: (1) explaining the medical issue, 
(2) reassuring the patient about receiving treatment, (3) estab-
lishing the uncertainty of the study team, (4) explaining the two 
arms of the trial, (5) giving a balanced description of treatment 
strategies and (6) explaining the trial- specific procedures. The 
model showed potential to enhance recruitment practice in trials 
seeking informed consent, but is unlikely to be directly transfer-
able to emergency and critical care trials that use RWPC.
We conducted a mixed- methods embedded study in a prag-
matic open- label paediatric emergency trial that compared two 
drugs for the second- line treatment of convulsive status epilep-
ticus, the ‘Emergency treatment with Levetiracetam or Phenytoin 
in Status Epilepticus in children’ (EcLiPSE), an open label, clini-
cian led trial’.12 There was a very low rate of declined consent 
in this trial (19/404, 4.7%).13 We used qualitative methods to 
explore how practitioners described the trial and RWPC by 
audiorecording recruitment discussions, and assessed how well 
this information was understood by interviewing parents within 
a month of the recruitment discussion. We aimed to use these 
data to help develop a framework adapted from the Realpe et al 
six- step model,11 and specifically designed to optimise recruit-
ment practices and parental understanding of paediatric emer-
gency and critical care trials using RWPC.
METHODS
Study design, setting and selection of participants
We conducted a mixed- methods embedded study (the Consent 
study) in all 30 UK sites which enrolled patients into EcLiPSE 
between July 2015 and April 2017, as reported previously.6 12 13 
All sites were member sites of Paediatric Emergency Research in 
the United Kingdom and Ireland (PERUKI,14 and composed of 
both tertiary and secondary level services, with variable levels of 
experience in enrolling patients into paediatric emergency care 
trials.
Qualitative methods included audiorecorded trial discussions 
between parents and practitioners. We conducted telephone 
interviews with parents approximately 1 month later. Our inten-
tion was to explore how practitioners described the trial and 
RWPC by audiorecording recruitment discussions, and then 
assessed how well this information was understood by inter-
viewing parents within a month of the recruitment discussion.
Audiorecorded trial discussions usually took place on a 
hospital ward within 24 hours of randomisation, and verbal 
and written consent was sought for all data collected. Practi-
tioners were asked to audiorecord all initial and subsequent trial 
recruitment and consent discussions with parents. LR (female 
health psychologist) arranged parental telephone interviews via 
email or telephone with the parent, and explained the consent 
study aims, objectives and research processes (eg, consent and 
confidentiality) prior to telephone interview. LR conducted all 
semistructured interviews using a consent study topic guide 
(online supplementary file 1) that explored parents’ experi-
ences of recruitment and consent processes, and trial accept-
ability and conduct. A range of sites were included to ensure 
sample variance. Sites were closed to consent study recruitment 
when five interviews had been conducted. Overall recruitment 
to interviews and recorded trial discussions were stopped when 
sample variance and data saturation (defined as the point where 
no new major themes were identified in ongoing analysis) were 
reached.15 16 Interviews and focus groups were transcribed 
verbatim by a professional transcription company. LR anony-
mised and checked transcripts for accuracy.
Data analysis
As shown in table 1, data analysis was interpretive and itera-
tive, referring back and forth between developing analysis and 
gathering new data. We aimed to explore how practitioner trial 
and RWPC explanations influenced parental understanding, and 
drew on the six- step model11 throughout (figure 1). LR initially 
analysed data from participants for whom trial discussions and 
parent telephone interview had been recorded (matched anal-
ysis). As part of a thematic approach,17 LR and KW (female, 
social scientist) explored the sequence and content of informa-
tion provision in trial discussions, as well as the information that 
was prioritised by parents when they reflected on the recruit-
ment discussion during interviews. These data were compared 
with matched interviews to determine whether any particular 
information facilitated parental understanding of the trial and 
RWPC. NVivo software was used to assist the organisation of 
qualitative data. We present selected interview quotations (with 
pseudonyms) that illustrate research themes across a range of 
participants. Where quotes have been shortened for brevity or 
to remove identifiable information, omitted text is marked with 
‘…’ and explanatory text is in brackets.
Patient and public involvement
Parents of children with epilepsy participated in pretrial qual-
itative research,18 which informed the design of EcLiPSE 
including RWPC processes.8 The EcLiPSE trial and embedded 
consent study team included a patient partner (a parent with 
relevant experience) as a member of the management team. 
They helped develop information materials and topic guides for 
the consent study and dissemination materials, such as an info-
graphic summarising EcLiPSE study findings for participants and 
members of the public.
RESULTS
A total of 193 children were randomised and treated in the 
EcLiPSE trial at sites participating in the Consent study. Parents 
of 95/193 (49%) children gave consent for audiorecorded trial 
discussions (figure 2), of which 76/95 (80%) were received and 
analysed. Of the 114 parents who agreed to be approached for 
interview, 59/114 (51%) were invited, 30 were interviewed and 
analysed. Of these, 19 were a matched data set (recorded trial 
discussions and parental interview related to one family) and 11 
were not matched. Interview and recorded trial discussions data 
related to EcLiPSE recruitment at 17/30 (57%) sites.
Just under half (36/76, 47%) of recorded trial discussions 
were led by doctors and 19/76 (25%) by the research nurses. The 
practitioner’s clinical background was unclear in 21/76 (27%) 
recordings. Many (45/76, 60%) recorded one trial discussion, 
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24/76 (31%) recorded two parts of a trial discussion (eg, part 
1 was initial trial information provision and part 2 was consent 
discussion and form completion a day later) and 7/76 (8%) 
recorded three or more parts where conversations took place on 
multiple occasions. In 37 (49%) cases only the second part of the 
conversation had been recorded.
Parental capacity
Parental capacity to understand or retain EcLiPSE trial informa-
tion appeared to be influenced by previous experience of their 
child having seizures. For example, parents of children who were 
admitted with their first seizure were often unable to recall the 
recruitment conversation or describe key aspects of the trial, 
even when a comprehensive explanation had been provided by 
practitioners. Poor recall was attributed to the highly emotive 
situation and often sleep deprivation.
‘I can’t remember….Yes, because I hardly slept. I stayed in the hos-
pital. I was constantly checking her, so it is really like a big blur to 
me.’ (Parent interview, mother, P4)
We found that trial recruitment discussions, including parental 
understanding of EcLiPSE and use of RWPC, were enhanced 
when using the seven steps shown in figure 3.
Step 1: explain the condition
The first step in the Realpe model (figure 1), ‘explaining the 
medical condition’, was often not explained or discussed during 
EcLiPSE discussions. This is likely due to the majority of parents 
in our sample having prior knowledge of their child’s epilepsy, 
thereby making an explanation redundant. However, this is not 
true of trials, and parents need an initial appropriately timed expla-
nation regarding the condition from the clinical or research team. 
This discussion should include how the condition, or suspected 
condition, relates to the research question. We have, therefore, 
placed this as the first step in our framework (figure 3)
Step 2: discuss trial purpose
EcLiPSE information posters and leaflets were available for 
placement in the resuscitation room or emergency department. 
However, parents reported they were only aware of the trial when 
they were approached by the recruiting practitioner after the emer-
gency situation had passed. Trial recruitment discussions often 
began with explanation of the trial aims and objectives and led 
to improved parental understanding and information retention. 
The following quote illustrates one mother’s clear recall of the trial 
purpose 1 month after a detailed description had been provided.
Table 1 Approach to data analysis and synthesis
Phase Description
1. Familiarising with 
qualitative data
Initially two complementary data- coding frameworks were developed for all interview and audiorecorded consent discussion data using broad a 
priori codes identified from initial reading related to the Consent Study aims and objectives including approach to recruitment and RWPC (please see 
our linked paper for further details of this stage 1 analysis (add reference to sister paper) .
Stage 2 analysis was then conducted for the 19 matched audiorecorded consent discussions and parental telephone interview data. LR listened to 
and read telephone interviews/transcripts and audiorecorded consent discussions/transcripts for each family and noted down initial ideas on themes.
2. Generating initial codes During the initial data familiarisation stage LR and KW identified data- driven codes and concepts. Analysis was based on a thematic analysis 
approach, a method for identifying, analysing and reporting patterns (or themes) within data.
3. Developing the coding 
framework
We then reflected on the Realpe framework and other data driven areas of interest from the stage 1 analysis and initial coding, to help organise 
matched data framework. We were interested in whether the health professional explained the uncertainty of the trial to the parents, gave the 
parents a balanced view of the two drugs, explained the study procedures well (eg, randomisation) and responded to questions and answers. LR 
organised data on each of these aspects of trial recruitment and other data- driven areas of interest. KW second coded 15% (n=3 matched data sets) 
of transcripts using a framework.
4. Defining and naming 
themes
Following review and reconciliation, LR and KW revised and ordered themes and related data into steps in an excel spreadsheet. The sequence and 
content of steps involved consideration what parents prioritised when they described aspects of the trial and the trial discussion during interviews, 
as well as of how the absence/presence of a particular step in the audiorecorded discussion appeared to hinder/help parental understanding when 
explored during their interview with LR. Regular weekly or bi weekly meetings were held to discuss the developing framework over a 3- month 
period.
5. Completion of coding of 
transcripts
In the final stage of analysis, LR considered the matched analysis framework (and related model) in reference to the wider data set (stage 1), which 
included an additional 11 interviews. This final stage aimed to ensure that the analysis and related model reflected aspects of recruitment and RWPC 
discussions that were important to all parents in the sample.
6. Write up LR and KW developed the initial manuscript. LR led the development of themes and KW developed the final model and manuscript write- up in 
collaboration with LR and MDL.
RWPC, research without prior consent.
Figure 1 A six step model for recruitment to an RCT (from Realpe et al).11 FAI, patient condition 'femoroacetabular hip impingement'.
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Basically that there's two medicines that they can give that they 
know stop seizures but they didn’t know which was the best one or 
the preferred one to use and that’s why you’re doing this study, to 
see how it affects different people (Parent interview, mother, P15).
In contrast, our analysis showed that brief verbal information 
provision by the practitioner was linked to poor parental under-
standing and poor recall of any aspect of the trial, even when 
information sheets had been provided. For example, one trial 
discussion (duration 3 min 27 s) briefly covered the trial aims, 
names of the two drugs and reassurance that their child received 
‘the normal treatment she would normally have anyway’ 
(Recorded trial discussion 2, trial recruiter). When interviewed 
this parent was unable to recall any details of the conversation: 
‘I can't remember’ (Parent interview, mother, P4).
Step 3: explain the reasons for conducting research without prior 
informed consent
Following discussion of the trial’s purpose, practitioners would 
then explain why informed consent could not have been sought 
before their child was entered in to the trial:
Obviously a lot of research studies you normally consent before 
you are entered into a study, but we had to do something called 
deferred consent because we put her into the study…because of the 
nature of the emergency department it is not appropriate to try and 
get consent while she is still fitting (Parent interview, father, P20).
Such explanations were most often well received. Although 
some parents stated they were initially surprised to discover their 
child had been enrolled without prior consent, an explanation of 
the reasons had helped alleviate parental concern.
I think the only thing I really found surprising was the whole in-
forming you about it afterwards…when he explained it all, I mean 
it makes sense. It’s not the situation to start having discussions, it's 
an emergency situation (Parent interview, mother, P14).
Step 4: establish uncertainty about which treatment is the best
When practitioners explained that they did not know which 
drug was better (ie, quicker at stopping long- lasting seizures), 
parents were clear about the uncertainty aspect of the trial; this 
was not clear when there was no explanation. The following 
illustrate a good example of this situation:
There are these two drugs, and one of them—we have used both 
of them for a long time but we have only used one of them in the 
emergency setting but we are wondering whether the other one 
might work well, better or worse (Recorded trial discussion 6, Trial 
recruiter).
What they explained was even though there were two drugs for 
children with Epilepsy, to try and control it…said they had both 
been used for years… they just wanted to know which drug would 
be best suited to control children with epilepsy (Parent interview, 
mother, P3, matched with recorded trial discussion 6).
Step 5: give a balanced description of the trial treatments
A balanced description of both drugs was often closely linked to 
explanations of uncertainty. Interventions in EcLiPSE were not 
blinded and therefore staff commonly informed parents which 
intervention their child had received. They sometimes spoke 
more positively about the drug received, or did not provide 
details of the other drug. Although a balanced description was 
provided in information sheets, tailored practitioner expla-
nations sometimes resulted in parents having an unbalanced 
understanding of the risks and benefits of the interventions and 
a potential for misunderstanding. The following example illus-
trates a parent who was given only minimal information about 
the allocated treatment. This parent was reassured that her child 
received the ‘usual treatment’ (phenytoin), yet had no knowl-
edge of the other intervention and therefore did not fully under-
stand the trial aims, treatments or potential risks and benefits of 
the interventions:
Figure 2 Parent characteristics by method.
Figure 3 A seven step framework to assist recruitment in trials that involve RWPC. RWPC, research without prior consent.
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Trial recruiter: It was the old one (your child received), not the 
new one.
Parent: Okay, yes. The Phenytoin?
Trial recruiter: ‘yes’ (Recorded trial discussion 5)
I think at first when you’re told your daughter is in a trial, you’re 
like what do you mean she’s in a trial but, at the end of the day, 
they would have given that medication anyway, so there’s no harm 
in that. (Parent interview, mother, P8, matched with recorded trial 
discussion 5).
Step 6: provide a clear explanation of randomisation
Practitioners often provided confident but simple descriptions of 
randomisation, which may have been helped by a tangible nature 
of the randomisation process, which was the opening of an 
envelope. When clear explanations were provided, parents were 
often able to recall accurate information and this was reflected 
in their use of very similar phrases or terms to those used by the 
research team:
It’s totally random yes. Now the way that we work is that we’ve got 
a box of envelopes out the back… all those envelopes are randomly 
filled beforehand, so we don’t know what we are going to get or 
anything like that. We open it up, inside is a sheet, and it says on 
it give this patient (Recorded trial discussion 18, Trial recruiter).
And actually the way that it was explained… we are given the 
choice of an envelope… but we would’ve given one of those [drugs] 
anyway (Parent interview, mother, P12).
However, some parents could not recall details of the rando-
misation process. This reflected a combination of no explanation 
of randomisation by the research team but also no prior knowl-
edge of randomisation by the parents:
I just know I know what randomised selection and stuff means any-
way. I couldn't really tell you how it was explained to me (Parent 
interview, mother, P27).
Step 7: check understanding and provide an opportunity for 
questions
Parents who gave a very positive description of the trial and 
who understood key aspects of the trial had developed a good 
rapport with practitioners. Matched analysis showed these prac-
titioners had longer discussions with parents and encouraged 
questions. Understanding was further enhanced and retained 
when parents were asked to describe what they had understood 
about the purpose of the trial towards the end of the discussion, 
as illustrated below:
What I have understood is that you have been using this new drug 
for years, but what you still want to know is the drug still capable 
of working or is there another way you can control kids who have 
fits like [child] has…without the research how are you going to 
know what is the best thing for the kids (Recorded trial discussion 
6, parent- matched with parent 3 interview quote shown in step 4).
DISCUSSION
This qualitative analysis of EcLiPSE trial recruitment and RWPC 
discussions and subsequent parental interviews, provide new 
insight into practices which facilitated parental understanding 
of trial purposes and processes. These data have allowed us to 
develop a bespoke framework to optimise the process of parent 
understanding and trial recruitment for future paediatric emer-
gency and critical care trials with RWPC.
While a number of steps from the six- step model11 (eg, discus-
sion of the trial’s aims and procedures and giving a balanced 
description of treatments) were incorporated into trial discus-
sions and facilitated parental understanding in the EcLiPSE trial, 
the sequence of information presented often differed; there was 
also the additional step describing RWPC. This sequence is likely 
to be unique to emergency and critical care trials, as many trial 
processes have already taken place at the point of a consent 
discussion.
The first two steps proposed by Realpe et al, explanation of 
the condition and reassurance about receiving treatment, were 
not always present in our data. This was evident in both sides of 
the consent discussion, including information provided by prac-
titioners and questions asked by parents. This is likely to reflect 
parents’ prior knowledge of their child’s condition, making an 
explanation of seizures unnecessary. However, this is important 
to consider in future ED trials as parents may not know their 
child’s diagnosis when the subject is initially raised. In a recent 
feasibility study19 exploring fluid treatment for presumed sepsis 
in children, some parents were not aware that their child had 
this diagnosis, and were upset to discover this when approached 
by the trial recruiter. We, therefore, believe it is an important 
step and that trial recruiters should check what parents know 
about their child’s condition and whether further clinical infor-
mation is needed before broaching research. This first step in 
our framework (figure 3) is aligned with CONNECT guidance 
on RWPC8 which recommends that research teams should check 
with clinical staff regarding the child’s condition and parental 
coping to guide appropriate timing. Discussions should include 
information about how the condition relates to the research 
question to enhance parental understanding.
Previous studies have shown that patients and family members 
often prioritise verbal over written trial information.4 10 20 21 This 
was observed in EcLiPSE, with parents’ descriptions of the trial 
closely mirroring the phrases and terms used by practitioners 
rather than the language in the information sheets. Practitioners 
were flexible in the sequence of information provided, suggesting 
they tailored the topics with each parent, rather than adhering to 
the information sheet. Intuitively and as has been shown previ-
ously, it is important that trial practitioners tailor discussions to 
parents’ questions, needs and perspectives.10 22 23 Nevertheless, it 
is important that an explanation of RWPC should be given at an 
early stage (step 3 in our framework). This will obviate or mini-
mise initial surprise or concern that parents may feel when they 
first hear about their child’s participation in a trial.4 5 19
In contrast to literature suggesting discussions about trial 
processes, such as randomisation, can be awkward and may 
be avoided by practitioners,10 24 25 practitioners in EcLiPSE 
gave confident yet simple descriptions of the trial. This likely 
reflected the EcLiPSE site training, which had enhanced confi-
dence among practitioners.6 We believe that descriptions of 
the randomisation process, which involved the opening of a 
prefilled envelope, rather than using a benign metaphor (eg, toss 
of a coin) aided understanding. When such explanations were 
not provided, parents remained unclear about trials processes 
as they did not have any prior knowledge about clinical trials 
methodology to draw on. We believe our seven- step model can 
be tailored for different trial designs. For example, we propose 
that discussions about the use of a placebo would logically fall 
under a description of trial treatments (step 5), while recruitment 
discussions in a double blind RCT may also include a description 
of the blinding process (step 6, randomisation).
Finally, our study and proposed framework adds to RWPC 
literature by highlighting the need for trial recruiters to appro-
priately time research discussions,3 8 conduct them sensitively 
and provide adequate time for discussion. It also demonstrates 
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the importance of checking parental understanding thereby 
allowing additional opportunities for practitioners to reiterate 
aspects of the trial which may not have been clearly explained 
or fully understood by parents. This seems to be particularly 
important for parents of children with no previous experience 
of their child receiving emergency treatment.
Limitations and future directions
Not all audiorecorded trial discussions could be matched with 
parent interviews. However, our ‘unmatched’ data corroborated 
our findings to inform the development of our seven- step frame-
work. We were unable to fully explore one element of Realpe’s 
model (‘show confidence and a relaxed manner’) as we relied 
on audiorecordings rather than direct observation. Most parents 
(75%) of children randomised and treated in EcLiPSE consented 
to participate in some aspect of the Consent study, and qualita-
tive recruitment stopped when data saturation was reached.15 16 
However, none of the 19/286 (4%) parents who declined their 
child’s involvement in EcLiPSE consented to take part in the 
consent study and therefore their views were not represented 
in the analysis. Although our framework confirmed a number 
of steps also shown in the Realpe model, it is an adaptation and 
requires further testing in future paediatric emergency and crit-
ical care trials.
CONCLUSIONS
We have provided a seven- step framework to optimise consent 
discussions and parental understanding in paediatric emergency 
and critical care trials. Recruitment discussions for trials in these 
settings which use RWPC are distinct from trials using prospec-
tive informed consent. The proposed framework provides a 
structured way of delivering trial information, including an 
explanation of why the research was conducted without prior 
informed consent. It is important to evaluate this framework in 
future trials and its impact on recruitment, practitioner confi-
dence in explaining RWPC and parent understanding of trial 
processes.
Twitter Mark D Lyttle @mdlyttle and Kerry Woolfall @kerry_woolfall
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